Related Experiment Videos
Immune regulation of mouse 5T2 multiple myeloma. I. Immune response to 5T2 MM idiotype
J W Croese1, C S Vissinga, W J Boersma
1TNO-Institute for Experimental Gerontology, Rijswijk, The Netherlands.
Abstract:
The transplantable murine multiple myelomas (MM) of the 5T series originated spontaneously in the aging C57BL/KaLwRij mice. These murine malignancies offer an excellent model for experimental studies on different aspects of the human disease. With the aim to look for new treatment modalities, the influence of idiotype-specific immune response on the 'take' and the development of the 5T2 MM was studied. In the first experiment, long-lasting subcutaneous immunizations of syngeneic mice with the 5T2 MM immunoglobulin (Ig) showed a dose dependent anti 5T2 MM Ig idiotype-specific response. The majority of the optimally immunized mice showed no 'take' or they had a prolonged survival after intravenous inoculation with the 5T2 MM cells. All control mice, nonimmunized or immunized with an irrelevant 5T14 MM Ig, developed 5T2 MM with a typical lethal course. In the second experiment, delayed type hypersensitivity (DTH) reaction to the 5T2 MM idiotype was studied. Subcutaneous immunizations of syngeneic mice with 5T2 MM Ig or with 5T2 MM bone marrow cells resulted in a specific DTH reaction 48 hours after challenge with 5T2 MM bone marrow cells. No DTH reaction was obtained when intravenous immunization was used. These results indicate that 5T2 MM is sensitive to idiotype-specific immune regulation; they constitute a basis for further studies on treatment of already established MM in vivo.
Insights
Idiotype-specific immune responses can prevent or delay the development of 5T2 multiple myeloma (MM) in mice. This study shows that targeting MM idiotype with immunization offers a potential new treatment strategy for this cancer.
Area of Science:
- Immunology
- Oncology
- Veterinary Medicine
Background:
- Multiple myeloma (MM) is a hematologic malignancy that remains challenging to treat.
- The 5T series of transplantable murine multiple myelomas (MM) provides a valuable model for studying human MM.
- Investigating novel therapeutic strategies for MM is crucial.
Purpose of the Study:
- To evaluate the impact of idiotype-specific immune responses on the 'take' and progression of 5T2 MM in a murine model.
- To explore the potential of idiotype-based immunotherapy for MM treatment.
Main Methods:
- Subcutaneous immunization of syngeneic mice with 5T2 MM immunoglobulin (Ig) or irrelevant 5T14 MM Ig.
- Intravenous inoculation of 5T2 MM cells into immunized and control mice.
- Assessment of delayed type hypersensitivity (DTH) reactions following immunization with 5T2 MM Ig or bone marrow cells.
Main Results:
- Optimally immunized mice demonstrated resistance to 5T2 MM 'take' or prolonged survival after tumor cell inoculation.
- Control mice (non-immunized or immunized with irrelevant Ig) developed fatal 5T2 MM.
- Specific DTH reactions were observed after subcutaneous immunization with 5T2 MM Ig or bone marrow cells, but not with intravenous immunization.
Conclusions:
- 5T2 MM is susceptible to idiotype-specific immune regulation.
- Idiotype-specific immunization can prevent or delay 5T2 MM development in mice.
- These findings support further research into in vivo MM treatment using idiotype-specific immune strategies.